Home › Posts tagged Epidermal Growth Factor Receptor (EGFR)
Blog Archives

The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer

Posted on by by Posted in Companion Test, Diagnostic, Personalized Medicine, PubMed Entry, Thasso Post, Theragenomic Medicine No Comments ↓

June 30, 2017 – The below citation from PubMed addresses an vey important issue associated with genetic testing in theragenomic and personalized medicine. It is the question if the genetic test used to stage, classify, or determine treatability of a disease with a given drug is accurate.

…

Read more ›

Tags: , , , , , , , ,

This is it: First blood test to detect EGFR gene mutations in NSCLC

Posted on by by Posted in Companion Test, Diagnostic, Personalized Medicine, Thasso Post, Theragenomic Medicine 1 Comment ↓

June 03, 2016 – This is a huge step in the application of theragenomic medicine in cancer patients in the quest to deliver highly individualized health care for patients. Thus, on June 01, the American Food & Drug Administration (FDA) approved the cobas EGFR Mutation Test v2,

…

Read more ›

Tags: , , , , , , , , , , ,

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation

Posted on by by Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine, Uncategorized No Comments ↓

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in December 2015.

…

Read more ›

Tags: , , , , , , ,

Necitumumab (Portrazza) approved for the treatment of advanced squamous non-small cell lung cancer (NSCLC)

Posted on by by Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments ↓

November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

…

Read more ›

Tags: , , , , , , ,

Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M

Posted on by by Posted in Genetic Predisposition, New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

November 14, 2015 – The American Food and Drug Administration (FDA) just granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso) was approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

…

Read more ›

Tags: , , , , , , ,

FDA Approves Companion Genetic Diagnostic Test for Erlotinib [Tarceva] in NSCLC

Posted on by by Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Thasso Post No Comments ↓

May 14, 2013 – The US Food and Drug Administration (FDA) today announced the approval of the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Erlotinib (Tarceva). This is the first FDA-approved companion diagnostic that can detect epidermal growth factor receptor (EGFR) gene mutations,

…

Read more ›

Tags: , , , , , , , , , ,

thasso: donate

thasso: conditions

thasso: newest tweets

 

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

RSS random genetics

RSS random science

  • Ultrapotent antibody mix blocks COVID-19 virus attachment September 25, 2020
    A mix of ultrapotent antibodies from recovered COVID-19 patients has been shown to recognize and lock down the infection machinery of the pandemic coronavirus and keep it from entering cells. Each of the antibody types performs these overlapping tasks slightly differently. A low-dose of the antibodies protected against infection in animal studies.
  • Low level alcohol use during pregnancy can impact child's brain development September 25, 2020
    A new study finds any alcohol use during pregnancy, even low levels, is associated with subtle, yet significant behavioural and psychological effects in children including anxiety, depression and poor attention.
  • An app monitors cancer patients' health status and rewards participation September 25, 2020
    Gamification is becoming increasingly common in educational settings, but can also be used in other fields such as health. Researchers at the Complutense University of Madrid and the University of Zaragoza have developed the Close2U application, which enables healthcare staff to monitor cancer patients' mood and physical discomfort using daily questionnaires. In return for the […]
  • An area of the brain where tumor cells shelter from chemotherapy in childhood leukaemia September 25, 2020
    Sometimes, the central nervous system harbours tumour cells that elude treatment and thus become one of the main sources of relapse. Research led by the Complutense University of Madrid has identified one of these locations in which the cells remain protected: the stroma of the choroid plexus, a structure in the brain ventricles responsible for […]
  • Trends in treatment, survival among women with advanced ovarian cancer September 25, 2020
    This observational study examined survival rates and the use of chemotherapy before surgery among women with advanced-stage epithelial ovarian cancer in the United States from 2004 to 2016.
Top